Lifestyle changes may reverse heart disease effects
Some simple lifestyle changes may help reverse the effects of heart disease. Sister Donna Hawk enrolled in a 12-week program at Cleveland Clinic.
See on wnyt.com
The medical industry is quickly adopting mobile technology as a means of connecting lay users with medical professionals. Increasingly, smartphone and tablet users are speaking to their doctors, scheduling medical appointments, and even receiving complex diagnoses via mHealth platforms.
mHealth makes it possible for consumers to receive personalized medical care that may otherwise be unavailable to these individuals.
In this article you can find cases that include some of the most successful mHealth developments to date.
See on www.slideshare.net
Transradial arterial access significantly lowers the risk of access site complications compared to transfemoral arteriotomy.
We analyzed 17 509 patients who underwent PCI at 5 institutions. Transradial arterial access was used in 17.8% of patients. In those who underwent transfemoral access, 177 (1.2%) patients had access site complications. Using preprocedural clinical and demographic data, a prediction model for femoral arteriotomy complications was generated. The variables retained in the model:
– elevated age (P<0.001)
– female gender (P<0.001
– elevated troponin (P<0.001)
– decreased renal function or dialysis (P=0.002)
– emergent PCI (P=0.01)
– prior PCI (P=0.005)
– diabetes (P=0.008)
– peripheral artery disease (P=0.003).
Patients with higher predicted risk of complications via transfemoral access were less likely to receive transradial access (P<0.001). Similar results were seen in patients presenting with and without ST‐segment myocardial infarction and when adjusting for individual physician operator.
Conclusions Paradoxically, patients most likely to develop access site complications from transfemoral access, and therefore benefit from transradial access, were the least likely to receive transradial access.
See on jaha.ahajournals.org
Personalized medicine tailors medical treatment to a patient’s personal history, genetic profile and specific biomarkers .
Pharmacogenetics (PGx) is an application of personalized medicine, referring to the process where patients are stratified and treated based on their genetic profile, which is used to assess expected drug response and the risk of adverse side effects. Traditional medicine typically relies on the broad application of “standard of care” or “one size fits all” treatments to all patients with a given diagnosis, irrespective of their genetic context.
The association between one’s gene variants and drug response rates or risks of adverse side effects to specific medications have been reported in many studies; in response, the US Food and Drug Administration (FDA) has updated the labels of nearly 100 drugs with recommendations for genetic testing prior to their use
Personalized Medicine has the potential to improve health outcomes and reduce the cost of care; however its adoption has been slow in Canada.
The main goal of the study was to explore the feasibility of utilizing personalized medicine in the treatment of chronic complex patients as a preliminary institutional health technology assessment.
We analyzed stroke treatment optimization as a clinical indication that could serve as a “proof of concept” for the widespread implementation of pharmacogenetics. The objectives of the study were three-fold:
1. Review current practice in medication administration for stroke treatment at Bridgepoint Health
2. Critically analyze evidence that pharmacogenetic testing could (or could not) enhance drug selection and treatment efficacy for stroke patients;
3. Assess the cost-benefit potential of a pharmacogenetic intervention for stroke.
Summary of results
The PGx-guided treatment approach has the potential to optimize drug treatment for complex continuing care patients who take a battery of medications for a prolonged period of time.
We have shown that genetic testing for antiplatelet medications and anticoagulants would greatly benefit prevention of secondary stroke, particularly in patients on clopidogrel or warfarin.
Specifically, PGx testing for clopidogrel metabolism is strongly recommended by the FDA and leading pharmacogenetic experts. It would be prudent of BPH to consider practical implementation of genetic testing for current and future clopidogrel users. Furthermore, an integrated approach for critical re-evaluation of the entire drug portfolio can add further value at minimal extra cost when expanding basic testing to include other gene variants.
Read the original with full text at http://www.clintransmed.com/content/2/1/16
See on www.clintransmed.com
Fiber-rich foods may cut risk of heart disease Visalia Times-Delta “With so much controversy causing many to avoid carbohydrates and grains, this trial reassures us of the importance of fiber in the prevention of cardiovascular disease,” said one…
See on www.visaliatimesdelta.com